RBC Capital Sticks to Its Hold Rating for PTC Therapeutics (PTCT)
Form 144 | PTC Therapeutics(PTCT.US) Director Proposes to Sell 764.77K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $PTC Therapeutics(PTCT.US)$ Director ZELDIS JEROME B intends to sell 20,000 shares of its common stock on May 22, with a total market value of approximately $764.77K.
Analysts' Revenue Estimates For PTC Therapeutics, Inc. (NASDAQ:PTCT) Are Surging Higher
PTC Therapeutics, Inc. (NASDAQ:PTCT) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus estimated revenue
Hold Rating on PTC Therapeutics Amid Regulatory Uncertainty for Translarna
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
PTC Therapeutics Price Target Raised to $53.00/Share From $43.00 by JP Morgan
PTC Therapeutics Price Target Raised to $53.00/Share From $43.00 by JP Morgan
PTC Therapeutics Is Maintained at Sell by Goldman Sachs
PTC Therapeutics Is Maintained at Sell by Goldman Sachs
Express News | Goldman Sachs Maintains Sell on PTC Therapeutics, Raises Price Target to $32
Express News | European Commission Asked CHMP To Review Its January Opinion On Renewal Of Marketing Authorization For Translarna
Express News | EMA : European Commission Asked Chmp to Review Its January Opinion on Renewal of Marketing Authorisation for Translarna
Express News | PTC Therapeutics Inc : Citigroup Raises Target Price to $26 From $18
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Conmed (CNMD) and PTC Therapeutics (PTCT)
Express News | PTC Therapeutics Inc : Raymond James Raises to Market Perform From Underperform
Express News | PTC Therapeutics Inc : JP Morgan Raises Target Price to $53 From $43
Translarna's Uncertain Future: Justifying a Sell Rating for PTC Therapeutics
Larimar Stock Rallies 24% on FDA Removal of Partial Clinical Hold
Sell Rating Maintained for PTC Therapeutics Amid Long-Term Revenue Growth Concerns
PTC Therapeutics Is Maintained at Buy by Jefferies
PTC Therapeutics Is Maintained at Buy by Jefferies
Express News | Jefferies Maintains Buy on PTC Therapeutics, Raises Price Target to $46
PTC Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/20/2024 15.81% Jefferies $35 → $46 Maintains Buy 04/29/2024 -24.47% Morgan Stanley $28 → $30 Upgrades U